Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 4/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 4/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.65 |
| ▸ | PRKACA | P17612 | 2/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.65 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.65 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.65 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | PRKCG | P05129 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | LYN | P07948 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | FLT4 | P35916 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910253 | 0.92 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL19864314 | 0.87 | MAPK14 (0.90) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL1640317 | 0.86 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL13819564 | 0.83 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL28489978 | 0.83 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL4915442 | 0.82 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL7720179 | 0.82 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11PRKD3 | |
| SCHEMBL4907875 | 0.81 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4586018 | 0.81 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4915290 | 0.80 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| EP-3553169-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-11-03 | — | — | EP | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| CN-103842362-A | Compositions and methods for treating Alzheimer's disease | EIP PHARMA LLC | 2014-06-04 | — | — | CN | claimed |
| EP-2707369-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2014-03-19 | — | — | EP | claimed |
| WO-2012154814-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | WO | claimed |
| EP-1196167-B1 | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions | LIPTON STUART A (US) | 2006-04-19 | — | — | EP | claimed |
| EP-0809499-B1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORP (US) | 2003-11-19 | — | — | EP | claimed |
| US-20030078274-A1 | Method of reducing neuronal injury or apoptosis | LIPTON STUART A (US) | 2003-04-24 | — | — | US | claimed |
| US-6387898-B1 | USING IMIDAZOLE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-05-14 | — | — | US | claimed |
| US-6096739-A | Treatment for CNS injuries | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078274-A1 | Method of reducing neuronal injury or apoptosis | GAP43, DCX, NLN | MAPK14 40/4885MAPK13 129/4885MAPK12 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.